Development and implementation of an innovative diagnostic process based on machine learning to shorten the patient treatment path and improve quality of health care for patients with lympho- and myeloproliferative diseases
Project title
Development and implementation of an innovative diagnostic process based on machine learning to shorten the patient treatment path and improve quality of health care for patients with lympho- and myeloproliferative diseases
Name of Beneficiary/Beneficiaries
Saventic Health Sp. z o.o.
Name of programme
Operational Program “Smart Growth”
Competition
Fast Track
Project value
PLN 1,919,673.39
Funding value
PLN 1,363,249.29
Project delivery period
01.12.2020 – 30.04.2023
Results of our work
Video
Issues addressed
As part of the project, artificial intelligence algorithms were developed for the early diagnosis of blood cancer diseases (lympho- and myeloproliferative). The algorithms were trained based on actual patient data obtained from hospitals and clinics with which cooperation was established for the project.
Thanks to the use of AI algorithms and natural language processing (which allows you to identify symptoms of a disease described in unstructured medical records, for example in descriptions of visits or results of radiological tests such as ultrasound or tomography), our product provides doctors with information about the potential risk of a rare disease in a given patient.
Based on laboratory results and symptoms documented in electronic health records (EHRs), each patient was assigned to one of two groups:
1. patients at low risk of developing blood cancers,
2. patients at increased risk of developing blood cancers. There are four types of cancer: (1) tumors of myeloid origin, (2) tumors of lymphoid origin, (3) acute leukemias, (4) undetermined blood cancers.
Project beneficiaries
The result of the project is dedicated for use by medical facilities and their staff (the direct recipient). It allows to shorten the process of diagnosing rare diseases and avoid costs of unnecessary diagnostic tests or consultations. The project’s beneficiaries are also patients with an undiagnosed rare disease, their families and the entire society (lower costs for the health care and social security systems by avoiding treatment without proper diagnosis).